Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Bernd Metzner, MD PhD, Jochen Casper, MD PhD, Koehne Claus-Henning, MD PhD, Andrea Renzelmann, MD, Thomas H. Mueller, MD PhD, Eduard K. Petershofen, MD PhD, Bernd Rosien, MD, Ruth Thole, MD, Andreas Voss, MD, Martin H. Dreyling, MD PhD, Eva Hoster, PhD, Wolfram Klapper, Christiane Pott, MD PhD

Blood (2019) 134 (Supplement_1): 2819.

https://doi.org/10.1182/blood-2019-122353

Published: 2019

Journal Articles

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Martin Dreyling, MD, Eva Hoster, PhD, Michael Unterhalt, PhD, Andreas Rosenwald, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Wolfram Klapper

Blood (2019) 134 (Supplement_1): 3996.

https://doi.org/10.1182/blood-2019-130068

Published: 2019

Journal Articles

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Blood (2016) 128 (22): 1102.

https://doi.org/10.1182/blood.V128.22.1102.1102

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group ( GLSG )

Vindi Jurinovic, M.Sc., Bernd Metzner, MD, PhD, Michael Pfreundschuh, MD, PhD, Norbert Schmitz, MD, PhD, Hannes Wandt, MD, PhD, Christian Peschel, MD, PhD, Martin Dreyling, MD PhD, Wolfgang Hiddemann, MD, PhD, Eva Hoster, PhD, Michael Unterhalt, PhD, Oliver Weigert, MD

Blood (2016) 128 (22): 3464.

https://doi.org/10.1182/blood.V128.22.3464.3464

Published: 2016

Journal Articles

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, PhD, Britta Kehden, Michael Unterhalt, PhD, Michael Herold, Richard H van der Jagt, Ann Janssens, MD, Michael Kneba, Jiri Mayer, MD, Chris Pocock, PhD FRCPath FRCP, Nathalie Danesi, PhD, Günter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Robert E Marcus, Wolfgang Hiddemann

Blood (2016) 128 (22): 613.

https://doi.org/10.1182/blood.V128.22.613.613

Published: 2016

Journal Articles

A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy

Blood (2015) 126 (23): 333.

https://doi.org/10.1182/blood.V126.23.333.333

Published: 2015

Journal Articles

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Christiane Pott, MD PhD, David Belada, MD PhD, Nathalie Danesi, PhD, Günter Fingerle-Rowson, MD PhD, John Gribben, MDDSc, Chris Harbron, MPhil, Eva Hoster, PhD, Brad S Kahl, MD, Kirsten Mundt, PhD, Catherine Sebban, MD, Laurie H Sehn, MD MPH, Bruce D. Cheson, MD

Blood (2015) 126 (23): 3978.

https://doi.org/10.1182/blood.V126.23.3978.3978

Published: 2015

Journal Articles

Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Eva Hoster, PhD, Andreas Rosenwald, MD, Francoise Berger, MD PhD, Heinz-Wolfram Bernd, Sylvia Hartmann, Christoph Loddenkemper, Thomas Barth, Nicole Brousse, Stefano Pileri, Grzegorz Rymkiewicz, Roman Kodet, Michael Unterhalt, MD, Johanna C. Kluin-Nelemans, Olivier Hermine, MD PhD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, Wolfram Klapper, MD

Blood (2014) 124 (21): 2977.

https://doi.org/10.1182/blood.V124.21.2977.2977

Published: 2014

Journal Articles

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

Marie-Hélène Delfau-Larue, MD PhD, Klapper Wolfram, MDPhD, Francoise Berger, Fabrice Jardin, MD PhD, Josette Briere, MD, Catherine Thieblemont, MD PhD, Pierre Feugier, MD PhD, Corinne Haioun, MD, Gilles Andre Salles, MD PhD, Vincent Ribrag, MD, Rene-Olivier Casasnovas, MD, Michael Unterhalt, MD, Martin Dreyling, Christiane Pott, MD PhD, Elizabeth Macintyre, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 1625.

https://doi.org/10.1182/blood.V124.21.1625.1625

Published: 2014

Journal Articles

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

Christiane Pott, M..D, PhD, Elizabeth Macintyre, MD PhD, Marie-Helene Delfau-Larue, MD PhD, Vincent Ribrag, MD, Michael Unterhalt, MD, Michael Kneba, MD PhD, Wolfgang Hiddemann, MD, Martin Dreyling, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 147.

https://doi.org/10.1182/blood.V124.21.147.147

Published: 2014

Journal Articles

Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study

Morgane Cheminant, Stephanie Schmit, Aurore Touzart, MD, Coralie Derrieux, MD, Marie-Hélène Delfau-Larue, MD PhD, Catherine Thieblemont, MDPhD, Vincent Ribrag, MD, Loic Ysebaert, MDPhD, Fabrice Jardin, MD PhD, Stephane Cheze, MD, Francois Lefrère, MD, Richard Delarue, MD, Christiane Pott, MD PhD, Eva Hoster, PhD, Martin Dreyling, Vahid Asnafi, MDPhD, Olivier Hermine, MD PhD, Elizabeth Macintyre, MD PhD

Blood (2014) 124 (21): 1657.

https://doi.org/10.1182/blood.V124.21.1657.1657

Published: 2014

Journal Articles

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, PhD, Michael Unterhalt, MD, Michael Pfreundschuh, Michael Hallek, MD, Roswitha Forstpointner, Bernd Metzner, Hermann Einsele, Jürgen Krauter, MD, Ulrich Dührsen, Wolf-Dieter Ludwig, Josef Birkmann, Norma Peter, Wolfram Klapper, MD, Martin H. Dreyling, Wolfgang Hiddemann, MD PhD

Blood (2014) 124 (21): 1752.

https://doi.org/10.1182/blood.V124.21.1752.1752

Published: 2014

Journal Articles

Monitoring of Bone Marrow Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation – Evaluation of a qPCR Based Chimerism Assay

Roland Reibke, MD, Andrea Dick, PhD, Max Hubmann, MD, Eva Hoster, PhD, Reinhard Henschler, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 3866.

https://doi.org/10.1182/blood.V124.21.3866.3866

Published: 2014

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Martin H. Dreyling, MD, Eva Hoster, PhD, Achiel Van Hoof, Bernd Metzner, Christian Gisselbrecht, Michael Pfreundschuh, MD, PhD, Marcel Reiser, Lorenz H. Truemper, MD, PhD, Hjalmar Steinhauer, Jean-Michel Boiron, MD, PhD, Marc Boogaerts, MD, PhD, Vittorio Silingardi, J.C. Kluin- Nelemans, MD, PhD, Michael Unterhalt, Wolfgang Hiddemann

Blood (2008) 112 (11): 769.

https://doi.org/10.1182/blood.V112.11.769.769

Published: 2008

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

NARROW

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group ( GLSG )

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Monitoring of Bone Marrow Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation – Evaluation of a qPCR Based Chimerism Assay

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only